Pancreatic Cancer Research

ResearcherYokohama City University HospitalActive in the last 2 years

Shingo Kato

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4785-5543; OpenAlex author ID A5101627677. Sources: OpenAlex.

Their work

Papers
7 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
23
Papers, trials and grants by year

2011: 2 papers · 2012: none · 2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: 2 papers · 2025: none · 2026: 1 paper

Papers 7

  1. A Combinatorial Effect of Immune Checkpoint Inhibitors and CD40 Agonistic Antibody in Murine Pancreatic Cancer Model. Co-author DOI 10.1111/cas.70246↗
  2. Clinical development of a blood biomarker using apolipoprotein-A2 isoforms for early detection of pancreatic cancer. Co-author DOI 10.1007/s00535-023-02072-w↗
  3. Identification of TPI1 As a potential therapeutic target in pancreatic cancer with dependency of TP53 mutation using multi-omics analysis. Co-author DOI 10.1111/cas.16302↗
  4. Use of Biomarkers and Imaging for Early Detection of Pancreatic Cancer. Co-author DOI 10.3390/cancers12071965↗
  5. Collapsin response mediator protein 4 expression is associated with liver metastasis and poor survival in pancreatic cancer. Co-author DOI 10.1245/s10434-012-2491-3↗
  6. Usefulness of endoscopic biopsy using FOXP3+ Treg up-regulation in the duodenal papilla in the differential diagnosis between autoimmune pancreatitis and pancr… First author DOI 10.1007/s00534-010-0359-0↗
  7. Semaphorin 4D, a lymphocyte semaphorin, enhances tumor cell motility through binding its receptor, plexinB1, in pancreatic cancer. Co-author DOI 10.1111/j.1349-7006.2011.02053.x↗

Closest collaborators

The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kazufumi Honda · 3 shared papers, 2020–2024 · strength 0.60
  2. Itaru Endo · 3 shared papers, 2011–2026 · strength 0.31
  3. Yukihiko Hiroshima · 2 shared papers, 2013–2026 · strength 0.29
  4. Shin Maeda · 2 shared papers, 2011–2026 · strength 0.28
  5. Juri Ichikawa · 1 shared paper, 2026 · strength 0.26
  6. Tomohiko Tamura · 1 shared paper, 2026 · strength 0.26
  7. Tomoaki Toyoda · 1 shared paper, 2024 · strength 0.21
  8. Ryuji Ohashi · 1 shared paper, 2024 · strength 0.21
  9. Akira Matsushita · 1 shared paper, 2024 · strength 0.21
  10. Ayumi Kashiro · 1 shared paper, 2024 · strength 0.15
  11. Michimoto Kobayashi · 1 shared paper, 2024 · strength 0.15
  12. Susumu Hijioka · 1 shared paper, 2024 · strength 0.15
  13. Satoshi Nara · 1 shared paper, 2024 · strength 0.15
  14. Sudhir Srivastava · 1 shared paper, 2024 · strength 0.15
  15. Giman Jung · 1 shared paper, 2024 · strength 0.15
  16. Ying Huang · 1 shared paper, 2024 · strength 0.15
  17. Chigusa Morizane · 1 shared paper, 2024 · strength 0.15
  18. Kensuke Kubota · 3 shared papers, 2011–2013 · strength 0.07
  19. Noritoshi Kobayashi · 3 shared papers, 2011–2013 · strength 0.07
  20. Masahiko Inamori · 2 shared papers, 2011 · strength 0.04
  21. Atsushi Nakajima · 2 shared papers, 2011 · strength 0.04
  22. Yasushi Ichikawa · 1 shared paper, 2013 · strength 0.03
  23. Hitoshi Nakagama · 1 shared paper, 2011 · strength 0.02

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.